Sci Rep:开胸手术中限制性液体管理与复合并发症的发生率更高相关

2020-05-26 xiangting MedSci原创

与更严格的液体管理相比,就复合并发症而言,术中净输液速度保持在4-5ml.kg-1.h-1与开胸手术的结局更好相关。

胸腔手术建议进行限制性液体管理。但是,缺乏具体的指导原则,并且限制性策略损伤肾脏灌注的担忧始终存在。这项研究目的是找到开胸手术中复合并发症(肺部并发症或急性肾损伤)发生率最低的术中净输液速度。研究假设一定范围的输液速度会减低术后30天内的复合并发症。

这项回顾性研究纳入在三级大学医院接受开胸手术的所有患者(n=1,031)。液体监测的时间范围是从手术开始到术后24小时。根据最小p值法,术中净输液速度的阈值为4-5ml.kg-1.h-1,因此将患者分为低速(≤3ml.kg-1.h-1)、阈值(4-5ml.kg-1.h-1)和高速组(≥6ml.kg-1.h-1)。阈值组复合并发症的发生率最低(低速、阈值和高速组分别为19%、12%和13%,P=0.0283;低速vs.阈值,P=0.0324,Bonferroni校正)。阈值组急性呼吸窘迫综合征的发生率最低(低速、阈值和高速组分别为7%、3%和6%,P=0.0467;低速vs.阈值,P=0.0432,Bonferroni校正)。在多因素分析中,术中净输液速度与复合并发症相关,并且阈值组的风险降低(比值比为0.54,95%置信区间:0.35-0.81,P=0.0035)。

总之,与更严格的液体管理相比,就复合并发症而言,术中净输液速度保持在4-5ml.kg-1.h-1与开胸手术的结局更好相关。

原始出处:

Jie Ae Kim. Restrictive intraoperative fluid management was associated with higher incidence of composite complications compared to less restrictive strategies in open thoracotomy: A retrospective cohort study. Sci Rep. 21 May 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1968910, encodeId=05be1968910cc, content=<a href='/topic/show?id=90a3496e791' target=_blank style='color:#2F92EE;'>#开胸手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49677, encryptionId=90a3496e791, topicName=开胸手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fc9246, createdName=zhangfenasdf, createdTime=Wed Nov 18 17:31:23 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826613, encodeId=83b7182661332, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue May 11 09:31:23 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758244, encodeId=c3ff1e5824498, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Mar 11 02:31:23 CST 2021, time=2021-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706365, encodeId=026b1e06365a8, content=<a href='/topic/show?id=6d0065896b0' target=_blank style='color:#2F92EE;'>#液体管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65896, encryptionId=6d0065896b0, topicName=液体管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=243631235324, createdName=fmq_28614563, createdTime=Mon Nov 16 20:31:23 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764219, encodeId=10541e64219dd, content=<a href='/topic/show?id=06b198243c3' target=_blank style='color:#2F92EE;'>#限制性液体管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98243, encryptionId=06b198243c3, topicName=限制性液体管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77137667724, createdName=12498bd5m28暂无昵称, createdTime=Thu Jun 11 12:31:23 CST 2020, time=2020-06-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1968910, encodeId=05be1968910cc, content=<a href='/topic/show?id=90a3496e791' target=_blank style='color:#2F92EE;'>#开胸手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49677, encryptionId=90a3496e791, topicName=开胸手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fc9246, createdName=zhangfenasdf, createdTime=Wed Nov 18 17:31:23 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826613, encodeId=83b7182661332, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue May 11 09:31:23 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758244, encodeId=c3ff1e5824498, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Mar 11 02:31:23 CST 2021, time=2021-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706365, encodeId=026b1e06365a8, content=<a href='/topic/show?id=6d0065896b0' target=_blank style='color:#2F92EE;'>#液体管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65896, encryptionId=6d0065896b0, topicName=液体管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=243631235324, createdName=fmq_28614563, createdTime=Mon Nov 16 20:31:23 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764219, encodeId=10541e64219dd, content=<a href='/topic/show?id=06b198243c3' target=_blank style='color:#2F92EE;'>#限制性液体管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98243, encryptionId=06b198243c3, topicName=限制性液体管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77137667724, createdName=12498bd5m28暂无昵称, createdTime=Thu Jun 11 12:31:23 CST 2020, time=2020-06-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1968910, encodeId=05be1968910cc, content=<a href='/topic/show?id=90a3496e791' target=_blank style='color:#2F92EE;'>#开胸手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49677, encryptionId=90a3496e791, topicName=开胸手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fc9246, createdName=zhangfenasdf, createdTime=Wed Nov 18 17:31:23 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826613, encodeId=83b7182661332, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue May 11 09:31:23 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758244, encodeId=c3ff1e5824498, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Mar 11 02:31:23 CST 2021, time=2021-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706365, encodeId=026b1e06365a8, content=<a href='/topic/show?id=6d0065896b0' target=_blank style='color:#2F92EE;'>#液体管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65896, encryptionId=6d0065896b0, topicName=液体管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=243631235324, createdName=fmq_28614563, createdTime=Mon Nov 16 20:31:23 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764219, encodeId=10541e64219dd, content=<a href='/topic/show?id=06b198243c3' target=_blank style='color:#2F92EE;'>#限制性液体管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98243, encryptionId=06b198243c3, topicName=限制性液体管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77137667724, createdName=12498bd5m28暂无昵称, createdTime=Thu Jun 11 12:31:23 CST 2020, time=2020-06-11, status=1, ipAttribution=)]
    2021-03-11 丁鹏鹏
  4. [GetPortalCommentsPageByObjectIdResponse(id=1968910, encodeId=05be1968910cc, content=<a href='/topic/show?id=90a3496e791' target=_blank style='color:#2F92EE;'>#开胸手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49677, encryptionId=90a3496e791, topicName=开胸手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fc9246, createdName=zhangfenasdf, createdTime=Wed Nov 18 17:31:23 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826613, encodeId=83b7182661332, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue May 11 09:31:23 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758244, encodeId=c3ff1e5824498, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Mar 11 02:31:23 CST 2021, time=2021-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706365, encodeId=026b1e06365a8, content=<a href='/topic/show?id=6d0065896b0' target=_blank style='color:#2F92EE;'>#液体管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65896, encryptionId=6d0065896b0, topicName=液体管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=243631235324, createdName=fmq_28614563, createdTime=Mon Nov 16 20:31:23 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764219, encodeId=10541e64219dd, content=<a href='/topic/show?id=06b198243c3' target=_blank style='color:#2F92EE;'>#限制性液体管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98243, encryptionId=06b198243c3, topicName=限制性液体管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77137667724, createdName=12498bd5m28暂无昵称, createdTime=Thu Jun 11 12:31:23 CST 2020, time=2020-06-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1968910, encodeId=05be1968910cc, content=<a href='/topic/show?id=90a3496e791' target=_blank style='color:#2F92EE;'>#开胸手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49677, encryptionId=90a3496e791, topicName=开胸手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fc9246, createdName=zhangfenasdf, createdTime=Wed Nov 18 17:31:23 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826613, encodeId=83b7182661332, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue May 11 09:31:23 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758244, encodeId=c3ff1e5824498, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Mar 11 02:31:23 CST 2021, time=2021-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706365, encodeId=026b1e06365a8, content=<a href='/topic/show?id=6d0065896b0' target=_blank style='color:#2F92EE;'>#液体管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65896, encryptionId=6d0065896b0, topicName=液体管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=243631235324, createdName=fmq_28614563, createdTime=Mon Nov 16 20:31:23 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764219, encodeId=10541e64219dd, content=<a href='/topic/show?id=06b198243c3' target=_blank style='color:#2F92EE;'>#限制性液体管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98243, encryptionId=06b198243c3, topicName=限制性液体管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77137667724, createdName=12498bd5m28暂无昵称, createdTime=Thu Jun 11 12:31:23 CST 2020, time=2020-06-11, status=1, ipAttribution=)]

相关资讯

DCR:体弱患者接受机器人手术治疗结肠癌会导致更严重的术后并发症的发生

目前微创手术越来越受到医生和患者的青睐,但是,人们对机器人手术对某些特定人群的影响(如体弱的患者)了解甚少。本项研究的目的是探究体弱患者与微创手术方法与结肠癌手术之间的关联。

BMJ: 不同围术期干预措施对预防术后肺部并发症

本项研究旨在评估有关不同围手术期的干预在减少成年非心脏手术成年患者术后肺部并发症(PPC)疗效的差异。

JAMA Cardiol:老年晚期心衰患者中与植入式心脏复律除颤器相关的围手术期风险和生存率

在接受ICD或CRT-D植入以预防心源性猝死的患者中,只有一小部分患者为晚期HF。与非晚期HF患者相比,这些患者与院内死亡和心脏骤停相关的临床重要围手术期并发症的发生率较高。

胃造瘘术后并发症的观察和处理

经皮内镜下胃造瘘(percutaneous endoscopic gastrostomy, PEG )是肠内营养的实施手段之一,主要适用于因需要长期接受营养支持的患者或无法经口进食者。

Clin Otolaryngol:与嗜酸性慢性鼻窦炎相关的并发症分析

嗜酸性慢性鼻窦炎(ECRS)是CRS的一种组织学亚型,并且治疗难度更大。与非ECRS患者相比,患有ECRS的患者症状更重,且鼻窦手术后治疗效果差。手术前ECRS的组织病理学和生物标志物评估通常是不可用

Eur Arch Otorhinolaryngol:耳蜗移植的手术并发症分析

尽管耳蜗移植技术已经很先进,但是相关的并发症发生率还是很高。最近,有研究人员使用紧密随访的一个大的患者群体数据进行了案例分析,鉴定了与耳蜗移植相关的并发症,并展现了他们使用的手术经验和技术,以遵循手术